SAN DIEGO, CA (Nov 8, 2016) - Biosortia Pharmaceuticals Inc. announces today that it is conducting an aquatic microbiome harvest from the Ellen Browning Scripps Memorial Pier on Tuesday, November 8 through Thursday, November 10. Microbiomes are being recognized by researchers as potential new opportunities in human health and drugs
Columbus, OH (May 16, 2016) - Ross Youngs is the person behind the US Department of Energy R&D project that led to the development of Biosortia's drug discovery platform. The platform can identify useful drug-like chemicals from microorganisms in water continuously. It is a way to continuously assay different microorganisms and keep finding more and more chemicals every day that could potentially be used in commercial medicine.
SAN DIEGO, CA (May 06, 2016) - Biosortia Pharmaceuticals has launched three new oncology research projects. The projects will investigate Biosortia's unique libraries of consortia microbial compounds for potential drug discovery in pediatric cancer (neuroblastoma), liver cancer (Hepatitis C virus) and an alternative approach to combat tumor growth by stimulating a patient's immune responses (immuno-oncology). The immune response strategy can have application across a range of cancer targets including pancreatic cancer, liver cancer, myeloma, neuroblastoma and ovarian cancer.
Columbus, OH (April 26, 2016) - Biosortia Pharmaceuticals has launched three new oncology research projects. The projects will investigate Biosortia's unique libraries of consortia microbial compounds for potential drug discovery in pediatric cancer (neuroblastoma), liver cancer (Hepatitis C virus) and an alternative approach to combat tumor growth by stimulating a patient's immune responses (immuno-oncology).
San Diego, California (February 25, 2016) - A brief explanation of what Biosortia does, how is it achieved, and why it is meaningful. Drug discovery directly from the chemistry of unculturable aquatic microorganisms in situ.
Columbus, Ohio (February 22, 2016) - Biosortia Pharmaceuticals announces today a contract with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) that gives the institution's cancer researchers access to novel natural product chemistry for the purpose of discovering and developing cancer-fighting therapeutics.
San Diego, California (January 11, 2016) - Biosortia Pharmaceuticals Inc. announces today that it has been selected by Johnson & Johnson Innovation - JLABS (JLABS) to operate as a resident company within its flagship JLABS facility in San Diego. Biosortia, a leader in drug discovery from unculturable microorganisms for cancer, infectious disease, central nervous system (CNS) and anti-inflammatory therapeutics also announced they will move their corporate headquarters to San Diego, California.
Dublin, Ohio (January 11, 2016) - Biosortia Pharmaceuticals, a leader in discovering and co-developing potent novel bio-active compounds with a primary focus on drug discovery for cancer, infectious disease, and anti-inflammatory therapeutics, has announced today that interim CEO, Ross O. Youngs will be presenting at Life Science Nation's RESI San Francisco.
Dublin, Ohio (December 31, 2015) - A startup seeking potential new drugs within blooms of algae has raised $500,000 and is moving its headquarters to San Diego to take part in a business accelerator run by pharmaceutical giant Johnson & Johnson.
Dublin, OH (December 17, 2015) - Biosortia Pharmaceuticals, a leader in discovering and co-developing potent novel bio-active compounds with a primary focus on drug discovery for cancer, infectious disease, and anti-inflammatory therapeutics, has announced today that interim CEO, Ross O. Youngs will be presenting at The 8th Annual Biotech Showcase.
Dublin, Ohio (November 19, 2015) - A Central Ohio startup seeking potential new drugs within blooms of algae is seeking a pharmaceutical industry "star" as its next CEO, which might require moving the headquarters to an industry hotspot if the recruit desires it.
Dublin, Ohio (November 12, 2015) - Biosortia Pharmaceuticals, a leader in discovering and co-developing potent novel bio-active compounds with a primary focus on drug discovery for cancer, infectious disease, and anti-inflammatory therapeutics, has announced today the appointment of Ross O. Youngs as interim CEO, effective immediately.
Author: Derek Parks | Dublin, Ohio (July 29, 2015) - The NOAA Ocean Service Hollings Marine Laboratory Cooperative Research and Development Agreement (CRADA), with Algaeventure Systems (dba Biosortia Pharmaceuticals), which was originally signed in 2012 and recently amended in 2014, has resulted in a wide array of successful outcomes for NOAA, and for its CRADA partners. Under the CRADA, NOAA is working with academia, industry and government entities that wish to screen toxic substances present in algal blooms for use pharmaceuticals and other commercial applications, while also producing mission-based data products for water quality managers and homeland security applications.
Dublin, Ohio (April 8, 2015) - Eli Lilly has recognized Dublin, Ohio based Biosortia Pharmaceuticals with the 2014 Open Innovation Drug Discovery (OIDD) Collaborator of the Year award.
Dublin, Ohio (August 21, 2014) - Biosortia's scout technologies make it possible to determine and prioritize the most optimal biomass harvesting sites as a source for new chemistry.
Dublin, Ohio (May 19, 2014) - The addition of Dr. He adds leadership and natural products drug discovery experience to Biosortia's Science Team. Dr. He has more than 20 years of experience in pharmaceutical R&D, specializing in discovery of drug leads from natural products and their semi-synthetic analogs in oncology, infectious disease, and other therapeutic areas.
Dublin, Ohio (April 2, 2014) - Biosortia is working with renowned drug discovery researchers at The Ohio State University, University of California Santa Cruz, Ole Miss and Purdue University.
Dublin, Ohio (July 15, 2013) - Biosortia Pharmaceuticals announced today a research agreement with AstraZeneca to screen Biosortia's library of unique natural products derived from aquatic microbial consortia for evaluation against AstraZeneca's therapeutic targets. The agreement includes the evaluation of partially refined mixtures as well as individual compounds.
Emily Mullin (July 9, 2013) - At a time when most of the biopharma industry has focused its preclinical research on screening synthetic compounds for their drug potential, Biosortia Pharmaceuticals is going back to nature to find promising compounds at the early stage of discovery.
Dublin, Ohio (June 11, 2013) - Dr. Nancy Sawtell, a professor and researcher at Cincinnati Children's Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in a collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of Biosortia's unique fractions and compounds for treatment of infectious diseases. With expertise in molecular mechanisms of herpes virus latency and reactivation, viral persistence, and pathogenesis, Dr. Sawtell will lend valuable experience to Biosortia's drug discovery efforts.
Dublin, Ohio (June 2013) - Dublin, Ohio based Biosortia Pharmaceuticals has accepted the offer to present at the Innovation Forum in New York City on June 27th at the Yale Club. Biosortia, a premier, aquatic natural products company, is building a library of potent, active and patented compounds with a primary focus on drug discovery in cancer, neurological, infectious, and inflammatory disease therapeutics. The creation of several patented disruptive technologies has positioned Biosortia to become a major player in the $500+ billion pharmaceutical industry, a market with its weakest pipeline in a decade.
Dublin, Ohio (May 2013) - The Centre for Marine Bioactives and Drug Discovery (MabCent-SFI) at University of Tromsø, Norway has entered into a collaborative relationship with Biosortia Pharmaceuticals of Dublin, Ohio to discover new biologically active natural products for the treatment of metabolic disorders. Research efforts are led by Dr. Steinar Paulsen with researchers at MabCent. The center's mission is to support research based innovation and is focused on marine bioprospecting, screening and characterization of bioactives for drug and biotechnological products.
Author: Kelsey Kaustinen | Dublin, Ohio (April 2013) - The Ohio State University (OSU) and Biosortia Pharmaceuticals have found that a great industry partner can be just down the street. The two Dublin, Ohio-based organizations have established an agreement to discover new biologically active natural products that demonstrate potential anti-cancer activity.
Biosortia will be sponsoring the research project, and compounds that result from the agreement will be tested primarily against human colon cancer assays, though it may eventually expand to include other cancer subtypes. Ultimately, the partners hope to identify lead compounds that can be licensed through Biosortia´s industry relationships to pharmaceutical companies for further development. The initial agreement was finalized by a collaboration between OSU´s Technology Commercialization and Knowledge Transfer Office and Office of Sponsored Programs.
Dublin, Ohio (March 12, 2013) - With up to 20,000 species in a liter of water, the aquatic environment could become the next frontier for drug discovery. What is in the water is earning more respect thanks to a new bio-tech company in Columbus. Biosortia Pharmaceuticals is in the business of "obtaining the unobtainable and finding medicine from nature to improve life." Inventor, scientist, entrepreneur and founder of Biosortia Pharmaceuticals, Ross O. Youngs, and its president & CEO, Kurt Dieck, shared the story of Biosortia Pharmaceuticals at the March 6, Columbus Metropolitan Club forum.
Dublin, Ohio (February 26, 2013) - The Ohio State University has signed an agreement with Biosortia Pharmaceuticals of Dublin, Ohio to discover new biologically active natural products with potential anti-cancer activity. Potential candidate compounds discovered during the Biosortia-sponsored research project will primarily be tested against human colon cancer assays. The ultimate goal is to obtain lead compounds that can be licensed to and developed by pharmaceutical companies through Biosortia's pharmaceutical industry relationships.
Dublin, Ohio (February 25, 2013) - On March 6th the Columbus Metropolitan Club at the Athletic Club of Columbus will host a lunch meeting where Biosortia Pharmaceuticals' President & CEO Kurt Dieck along with founder Ross Youngs will share a look at the vast potential for a whole new world of bio-pharmaceutical drug discovery from aquatic consortia.
Dublin, Ohio (February 11, 2013) - Ross Youngs Founder of Biosortia Pharmaceuticals accepted a Proclamation as an Entrepreneurial representative that recognizes how vital entrepreneurship is to growth and prosperity from Timothy A. Lecklider, Mayor of Dublin Ohio. Recognition to Tech Columbus, the Dublin Entrepreneurial Center, and National Entrepreneurship Week were highlighted during the presentation.
Ross thanked the Mayor and the City Council members and made brief comments.
Author: Carrie Ghose | Columbus, Ohio (February 1, 2013) - The same mystery toxins from blooms of algae that sicken swimmers and kill fish also might be the source of drugs to fight cancer or drug-resistant bacteria.
Biosortia Pharmaceuticals, a subsidiary of Marysville-based Algaeventure Systems Inc., is prospecting wild waterways for rare and previously unidentified chemicals that could be licensed to drug makers, akin to how penicillin was discovered in bread mold.
Columbus, Ohio (January 28, 2013) - A startup prospecting mucky ponds for pharmaceutical promise has hired two top executives with Fortune 100 experience. Biosortia Pharmaceuticals, a Dublin-based subsidiary of Marysville-based Algaeventure Systems Inc. announced its CEO is Kurt Dieck, who until late 2011 was senior vice president of strategy and business execution at Cardinal Health Inc. (NYSE:CAH).
Dublin, Ohio (January 22, 2013) - Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.
Dieck has spent nearly 30 years in healthcare, including 18 years at Arthur Andersen as a global equity partner and then 10 years with Cardinal Health, a Fortune 20 public company, as a senior executive; there he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Dr. Guy Carter has over 30 years of experience working in pharmaceutical R&D, primarily in the discovery and development of microbial natural products. He previously was the leader of natural products drug discovery at Wyeth Research, as head of the Chemical Technologies Department.
Author: Derek Parks/Friday, December 21, 2012 - The U.S. Department of Commerce, National Oceanic and Atmospheric Administration (NOAA), National Ocean Service, National Centers for Coastal Ocean Service, Center for Human Health Risk at Hollings Marine Laboratory (CHHR/HML) and Biosortia Pharmaceuticals dba Alagaeventure Systems (AVS) entered into a CRADA.